Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT00777959 | Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) | completed | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2015 | clinicaltrials |
| NCT01897207 |
| Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer |
| completed |
| Phase 1 / Phase 2 |
| 15 |
| Cantonal Hospital of St. GallenOTHER |
| 0 |
| Aug 17, 2015 |
| clinicaltrials |
| NCT00514267 | An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | completed | Phase 1 / Phase 2 | 32 | Astellas Pharma IncINDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01561482 | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | withdrawn | Phase 2 | 0 | Nicholas MitsiadesOTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00936975 | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01436214 | Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | unknown | Phase 1 / Phase 2 | 60 | Adamis Pharmaceuticals CorporationINDUSTRY | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00108732 | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT02049190 | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 75 | Arno TherapeuticsINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00058539 | Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer | completed | Phase 2 | 42 | Genentech, Inc.INDUSTRY | 0 | Jun 23, 2015 | clinicaltrials |
| NCT01705652 | Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients(Nexrutine) | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT02424513 | A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer | withdrawn | Phase 2 | 0 | ImaginAb, Inc.INDUSTRY | 1 | Jun 2, 2015 | clinicaltrials |
| NCT00118066 | Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia | terminated | Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00743379 | Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 71 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00715104 | Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer(NeoACT) | completed | Phase 2 | 42 | DendreonINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00020254 | Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00500110 | Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | completed | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00975429 | Study Using WST11 in Patients With Localized Prostate Cancer | completed | Phase 2 | 86 | Steba Biotech S.A.OTHER | 3 | Apr 28, 2015 | clinicaltrials |
| NCT02425163 | Shear Wave Elastography of Prostate Cancer(ElaProC) | completed | Phase 2 | 73 | University of MagdeburgOTHER | 1 | Apr 23, 2015 | clinicaltrials |
| NCT00673127 | Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer(KHAD) | completed | Phase 2 | 57 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 22, 2015 | clinicaltrials |
| NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 2 | University of KentuckyOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT02420587 | AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2015 | clinicaltrials |
| NCT00217464 | Fulvestrant in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00215683 | An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer | completed | Phase 2 / Phase 3 | 137 | Ferring PharmaceuticalsINDUSTRY | 7 | Apr 1, 2015 | clinicaltrials |
| NCT01267266 | Saracatinib in Treating Patients With Prostate Cancer | terminated | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00260611 | Study of Oxaliplatin and Taxotere in Prostate Cancer | completed | Phase 2 | 34 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01533246 | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00080899 | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00694291 | Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01565512 | Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort | withdrawn | Phase 1 / Phase 2 | 0 | Columbia UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01242631 | Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer(RADIT) | completed | Phase 2 | 25 | Hannover Medical SchoolOTHER | 1 | Feb 25, 2015 | clinicaltrials |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT02159690 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | withdrawn | Phase 2 | 0 | Kenneth Pienta, MDOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00151086 | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 33 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2015 | clinicaltrials |
| NCT00150995 | Tetrathiomolybdate in Hormone Refractory Prostate Cancer | completed | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00151047 | Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer | completed | Phase 2 | 15 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00151060 | Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | completed | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00134355 | Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer | completed | Phase 2 | 5 | University of Michigan Rogel Cancer CenterOTHER | 0 | Jan 19, 2015 | clinicaltrials |
| NCT00913263 | An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate(2-HOF) | completed | Phase 1 / Phase 2 | 24 | Lidds ABINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT02065323 | A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT | withdrawn | Phase 2 | 0 | Oscar Goodman, Jr.OTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT02342054 | Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer(SINFRA_PROST) | unknown | Phase 2 | 49 | Hospital de CrucesOTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00666666 | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01469338 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | terminated | Phase 2 | 9 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01531205 | Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00918385 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer(ARS) | terminated | Phase 2 | 57 | Duke UniversityOTHER | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00751205 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | completed | Phase 2 | 150 | BayerINDUSTRY | 6 | Oct 28, 2014 | clinicaltrials |
| NCT00683475 | A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | completed | Phase 2 | 138 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 16, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2015source: clinicaltrials